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Abstract 
Unconfounded comparative data on the type and dose of immunosuppressive agents among solid 
organ transplant recipients is sparse, as is data on longitudinal immunosuppressive therapy since 
transplantation. We addressed this issue in a population-based cohort of Australian liver (n=1895), 
heart (n=1220), and lung (n=1059) transplant recipients, 1984-2006. Data on immunosuppressive 
therapy was retrospectively collected at discharge, 3 months and 1, 5, 10 and 15 years after first 
transplant. We computed unadjusted and adjusted estimates for the association between the type and 
dose of immunosuppressive therapy and organ type. After adjustment for confounders, use of 
induction antibody and maintenance corticosteroids was more common in heart and lung compared to 
liver recipients (p<0.001), and antibody therapy for rejection more common in liver recipients 
(p<0.001). Liver recipients were more likely to receive calcineurin inhibitor monotherapy, with or 
without corticosteroids, compared to heart and lung recipients (p<0.001). Liver recipients consistently 
received lower doses of azathioprine than heart and lung recipients (p<0.001). These differences in 
immunosuppression may partly explain variations in immunosuppression-related morbidity by 
transplanted organ, for example malignancy risk. Longitudinal changes in the type and the dose of 
immunosuppressive therapy over time since transplantation also demonstrate the need for time-
dependent data in observational research. 
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INTRODUCTION 
Immunosuppressive therapy is critical to patient survival in solid organ transplantation but is 
associated with a range of side-effects including toxicity, infection, diabetes, cardiovascular disease, 
and cancer. Immunosuppressive agents are carefully chosen and titrated to achieve a balance between 
graft function and risk of harm from over-immunosuppression. Patient characteristics determine the 
initial type and dose of immunosuppressive agents, while the occurrence of side-effects, new evidence 
regarding clinical efficacy, as well as the availability of novel therapies and enrolment in clinical trials 
influence decisions to switch agents following transplantation. 
 
Clinical practice guidelines and OPTN/SRTR data indicate key differences in immunosuppression 
practice by organ type. For example, the use of induction antibody is less common in liver compared 
to heart and lung transplantation (1). Further, calcineurin inhibitor (CNI) monotherapy with 
corticosteroid withdrawal is generally only considered in highly selected low-risk heart transplant 
recipients, whereas it is recommended for a substantial proportion of liver recipients at one year post-
transplantation(1-5). However, there has been no comparison of immunosuppressive drug regimen 
and dose by organ type taking into account important demographic and clinical differences between 
patient groups. Moreover, there is no longitudinal data showing the extent of changes in 
immunosuppressive therapy over time since transplantation. 
 
To better understand the potential role of immunosuppressive therapy in immunosuppression-related 
morbidity, we compare the type, dosage, and combinations of immunosuppressive agents used by 
population-based cohorts of Australian liver, heart, and lung transplant recipients (1984-2006). 
 
PATIENTS AND METHODS  
Study population 
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We performed a retrospective population-based cohort study of Australian liver (n=1926), heart 
(n=1518), and lung (n=1200) recipients transplanted 1984-2006. Transplant recipients were registered 
on the Australia and New Zealand Liver Transplant Registry (1985+) or the Australia and New 
Zealand Cardiothoracic Organ Transplant Registry (1984+). We obtained ethical approval from all 
relevant institutions. 
 
Data collection 
The two registries prospectively collected demographic and some clinical data including organ type, 
primary transplant indication, transplant date, age at transplant, sex, and date of death. We 
supplemented these records with data abstracted from medical records at all Australian transplantation 
units (18 units at 12 hospitals). We ascertained recipient’s weight and prescribed immunosuppressive 
agents around the time of transplantation (i.e. induction therapy), at 3 months and 1, 5, 10 and 15 
years after transplantation (i.e. maintenance therapy), and during episodes of treated rejection. 
 
We recorded use of antibodies including interleukin-2 receptor antibodies (IL-2Ra; basiliximab, 
daclizumab), and T-cell depleting antibodies, both monoclonal (muromonab-CD3) and polyclonal 
(anti-thymocyte/anti-lymphocyte globulins, ATG/ALG), during induction therapy and rejection 
episodes. We documented the receipt of individual immunosuppressive agents and their doses 
(mg/day or mg/kg/day). 
 
We collected use of the CNIs cyclosporine and tacrolimus, the antiproliferatives azathioprine, 
mycophenolate (mycophenolate mofetil or enteric-coated mycophenolate sodium), and the mTOR 
inhibitors (mTORi) sirolimus and everolimus. We did not distinguish the different formulations of 
ATG/ALG, cyclosporine or tacrolimus. We collected use of maintenance oral corticosteroids and 
intravenous corticosteroid pulse therapy at induction and at up to three rejection episodes, but we did 
not differentiate the type (cellular or humoral) or severity of acute rejection. 
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Data preparation 
We followed-up organ recipients from the date of first transplant until re-transplantation, 80 years of 
age, death, or the end of follow-up (31 December 2006), whichever occurred first. In Australia, 
tacrolimus and mycophenolate were approved by the Therapeutic Goods Administration in 1997, and 
sirolimus and everolimus in 2002 and 2005, respectively. However, tacrolimus and mycophenolate 
were used from 1995, and sirolimus from 1998, in clinical trials in Australia. We therefore categorized 
transplant period according to the broad availability of immunosuppressive agents for our cohort; 
1984-1994, 1995-1997, and 1998-2006. We included all drug use, whether it was approved use, 
approved only under a special access scheme (Section 100 of the Australian Pharmaceutical Benefits 
Scheme), or in clinical trial. 
 
Recipient weight was used to standardize the dose of individual agents to mg/kg/day. As weight was 
not recorded at all observation times we imputed the missing values from a linear mixed model 
including age at transplantation, sex, and weight at other observation times for the same individual (6, 
7). 
 
We converted all doses of mycophenolic acid to equivalent doses of mycophenolate mofetil (8). We 
reviewed the immunosuppressive therapy data and identified potential outlying dose values (i.e. >1.5-
times the interquartile range (IQR) from the lower or upper quartile dose). Such values were changed 
to missing, unless there was a clear and logical pattern within the individual record, in which case they 
were retained. As the type and dose of individual immunosuppressive agents was not recorded at all 
observation times the missing data were imputed, where possible, by carrying the last observation 
forward to the next follow-up point. This is the conventional method for imputing longitudinal 
medication data, especially a combination of binary (drug type) and continuous (drug dose) data 
where most recipients received more than one immunosuppressive agent, with the dose of one agent 
likely to be related to the dose of the other due to drug-drug metabolic interactions (9). 
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Data analysis 
We compared the use of antibodies for induction, antibodies for rejection, corticosteroid therapy, and 
each maintenance immunosuppressive agent by organ type, and other recipient subgroups (e.g. age, 
sex) using Pearson's chi-square test or Fisher's exact test as appropriate. We used the Kruskal-Wallis 
non-parametric test to compare the median dose of each immunosuppressive agent for recipient 
subgroups; we applied a post-hoc multiple comparison procedure for non-parametric pairwise 
differences following a significant result (10). We demonstrated the change in dose by time since 
transplantation by plotting box-and-whisker plots; time trends were evaluated using the Mann-Kendall 
trend test. 
 
We wanted to study the association between organ type and the receipt of induction antibody, 
antibody rejection, each maintenance immunosuppressive agent (both type and dose) and the number 
of agents (monotherapy vs. combination therapy). We therefore needed to consider potential 
confounding factors that also varied by organ type and affected immunosuppression, such as recipient 
age at transplantation, sex, race, history of dialysis, history of diabetes, and transplant year. Using 
logistic regression we computed unadjusted and adjusted estimates for the receipt of 
immunosuppression by organ type, and retained covariates with p-values less than 0.20. For 
corticosteroids the maximum likelihood estimation did not converge due to quasi-complete separation 
of data, thus adjusted estimates were not possible. We modelled the adjusted median dose of each 
immunosuppressive agent by organ type using quantile regression (11). Analyses were carried out 
based on both original and imputed data. 
 
Analyses were performed using SAS 9.3 (SAS Institute, Inc., Cary, USA), STATA 11.0 (StataCorp 
LP, College Station, Tex) or R statistical software version 3.1.3 (R Development Core Team, 2014). 
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RESULTS 
Cohort characteristics 
We excluded recipients with no retrievable transplantation medical records (n=89) and those with 
some clinical but no immunosuppression therapy data (n=381; Figure 1). The eligible cohort consisted 
of 4174 transplant recipients, 1895 (46%) liver, 1220 (29%) heart, and 1059 (25%) lung, of whom 405 
(302 liver, 83 heart, and 20 lung) were pediatric (0-15 years at transplant). The median follow-up time 
was 5.6 years (IQR 2.4-10.2). We found significant differences in the distribution of transplant year 
and recipient and donor characteristics among organ types (Table 1). 
 
Recipient weight was not recorded at 27% of observation times. We found no difference in median 
recipient weight at each observation time before and after imputation (data not shown). The type and 
dose of individual immunosuppressive agents was missing at 18% and 31% of all observation times, 
respectively. The prevalence and median dosages of individual agents were comparable before and 
after imputation (data not shown). Although imputation attenuated the results obtained based on the 
original data, the statistical significance of the findings remained and the conclusions were unchanged 
(data not shown). The results presented are based on imputed data. Seventy-two percent of the cohort 
(n=3019) had complete data on immunosuppressive agents for the entire follow-up time. 
 
Induction therapy 
Induction antibody was most common for heart recipients (42%), adults (23%), and those transplanted 
in the earliest period (1984-1994; 37%). Induction antibody use was also more common in liver 
recipients with alcoholic liver disease compared to other primary indications and in those with a 
history of dialysis and intravenous corticosteroids (data not shown). Use of ATG/ALG and 
muromonab-CD3 decreased substantially after 1984-1994 and IL-2Ra was the most common 
induction antibody therapy in the latest period (1998-2006; 11%). After adjustment by the above 
confounders, induction antibody therapy during this recent period was significantly more common in 
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heart (odds ratio, OR 8.22, 95%CI 5.18-13.2) and lung (OR 5.87, 95%CI 3.78-9.21) compared to liver 
recipients. 
 
Therapy for acute rejection 
Treatment for acute rejection was most common for liver recipients (44%), pediatric patients (49%), 
and those transplanted in the earliest period (1984-1994; 50%). Intravenous corticosteroid pulse was 
the most frequent therapy (86% of those treated and 29% of all transplant recipients); only 8% of 
transplant recipients received antibody therapy, most commonly liver recipients (10%). The use of 
antibodies decreased significantly over time, from 17% in 1984-1994, to 9% in 1995-1997, and 4% in 
1998-2006 (p<0.001). Antibody rejection therapy was more common in recipients who were younger, 
female, had no intravenous corticosteroids, and those who did receive antibody induction therapy 
(data not shown). After adjustment by the above confounders, antibody rejection therapy was 
significantly more common in liver (OR 1.84, 95%CI 1.27-2.70) and lung (OR 2.19, 95%CI 1.29-
3.68) compared to heart recipients. 
 
Maintenance immunosuppressive therapies 
At least 85% of the cohort received oral corticosteroids 3 months after transplantation. Receipt of 
corticosteroids decreased over time from transplantation only for liver recipients; 34% of liver 
recipients were corticosteroid-free 5 years after transplantation, compared to 28% of heart and 1% of 
lung recipients. In unadjusted analyses, compared to heart and lung, liver recipients were significantly 
less likely to use corticosteroids at all follow-up times (p<0.001, data not shown). 
 
We observed the expected changes in maintenance immunosuppressive regimens by transplant era, 
from predominantly cyclosporine and azathioprine in 1984-1994 to a more varied mix of regimens 
and single agents in 1998-2006 (Supplementary Figures 1-4). We found marked differences in 
maintenance immunosuppressive regimen by organ type, year of transplant, and time since 
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transplantation (Figures 2-4). Overall, the use of cyclosporine declined over time after the introduction 
of tacrolimus. Similarly, azathioprine use decreased and mycophenolate increased over time, although 
the extent of these changes was greater than for the CNIs. 
 
Across all periods, a greater proportion of liver recipients received CNI monotherapy than heart and 
lung recipients at all follow-up times (p<0.001, data not shown). CNI monotherapy was less common 
in recent years and during 1998-2006, 35-50% liver, 3-4% heart and 10% lung recipients received 
monotherapy. There was also variation by age, sex, race, primary indication, dialysis history, diabetes 
history, antibody induction therapy, and recipient CMV serostatus at transplantation (data not shown). 
After adjustment by these confounders, liver recipients were more likely to receive monotherapy 
compared to heart and lung recipients at 3 months, 1 year and 5 years post-transplantation (p<0.001). 
 
The unadjusted frequency of use of individual immunosuppressive agents and drug combinations over 
time since transplantation by organ type for the three periods (1984-1994, 1995-1997 and 1998-2006) 
are shown in Figures 2-4. Overall, regimens were more likely to change with increasing time since 
transplantation. For patients transplanted in the most recent period (1998-2006), after adjustment for 
age, sex, race, transplant year, primary indication, dialysis history, diabetes history, antibody 
induction therapy, and recipient CMV serostatus at transplantation, lung and heart recipients were 
more likely to receive cyclosporine at 3 months (OR (95%CI): 17.0 (8.67-35.2) and 11.2 (5.57-23.6), 
respectively), 1 year (9.45 (4.84-19.1) and 9.08 (4.49-18.9)) and 5 years (3.34 (1.21-9.62) and 7.17 
(2.58-21.4)) compared to liver recipients. Heart recipients were also more likely to receive 
mycophenolate (6.04 (3.01-12.2), 6.76 (3.27-14.2) and 9.13 (3.26-26.9) at 3 months, 1 year and 5 
years, respectively) and lung recipients azathioprine (2.52 (1.43-4.54), 3.30 (1.78-6.17) and 4.48 
(1.57-13.4) at 3 months, 1 year and 5 years, respectively) than liver recipients. Liver recipients, on the 
other hand, were more likely to receive tacrolimus compared to heart and lung recipients at 3 months, 
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1 year and 5 years (p<0.001). There were no differences between heart and lung transplant recipients. 
All of these differences were maintained when only adult recipients were considered. 
 
Dose of immunosuppressive agents by time since transplantation 
The unadjusted median dose of several immunosuppressive drugs decreased with increasing time 
since transplantation, particularly the first 5 years (Supplementary Figures 5-6). For the entire cohort 
the reduction in median dose over 5 years was around 50% for CNIs and 20-30% for antiproliferative 
agents. Dosages were stable between 5 and 10 years, except for cyclosporine, which continued to 
decline (p<0.05). Between 3 months and 10 years after transplantation the median dose of 
cyclosporine and mycophenolate significantly decreased for all transplanted organs (p<0.05), the 
median dose of azathioprine significantly declined for heart and lung transplant recipients (p<0.001), 
but not liver, and the median dose of tacrolimus significantly declined for liver and lung recipients 
(p<0.05) but not heart (Supplementary Figures 5-6). 
 
Dose of immunosuppressive agents by recipient subgroup 
The unadjusted median dose of several individual immunosuppressive agents differed significantly by 
recipient age, sex, year of transplant, and primary indication (data not shown). Overall, higher dosages 
per kg were received by pediatric compared to adult recipients (and their corresponding primary 
indications), females compared to males, and those transplanted during the early compared to the 
latest period. 
 
Figures 5-7 and Supplementary Table 1 show the median dose of immunosuppressive agents by 
transplanted organ before and after adjustment for potential confounders at 3 months, and 1 and 5 
years after transplantation. After adjustment, compared to heart transplant recipients, liver recipients 
received a lower dose of azathioprine at all follow-up times (p<0.001), a lower dose of mycophenolate 
at 3 months and 1 year (p<0.001), a higher dose of cyclosporine at 5 years (p<0.001), and no 
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difference in tacrolimus dose. After adjustment, compared to lung transplant recipients, liver 
recipients received a lower dose of azathioprine (p<0.05) at all follow-up times, a lower dose of 
tacrolimus at 1 year (p<0.05), a higher dose of cyclosporine at 5 years (p<0.05), and no difference in 
mycophenolate dose. Compared to lung recipients, heart recipients received a lower dose of 
cyclosporine at 1 year (p<0.05), a higher dose of azathioprine at 1 and 5 years (p<0.05), and no 
difference in mycophenolate or tacrolimus dose. 
 
DISCUSSION 
We have documented the longitudinal use and dosage of immunosuppressive agents for a national 
population-based cohort of solid organ transplant recipients. As expected, with increasing time since 
transplantation the median dose of most individual agents declined, and regimens were more likely to 
change. Liver recipients were less likely to receive corticosteroids than heart and lung recipients. Our 
novel approach, adjusting for potential confounders, demonstrated significantly lower use of induction 
antibodies in liver compared to heart and lung recipients, and significantly more common antibody 
rejection therapy in liver and lung compared to heart recipients. Adjusted models also showed liver 
recipients were more likely to receive CNI monotherapy, with or without corticosteroids, compared to 
heart and lung recipients. Moreover, liver recipients consistently received lower doses of azathioprine 
compared to heart and lung recipients. These statistically and clinically significant differences in 
iatrogenic immunosuppression among organ recipients may contribute to differences in post-
transplantation morbidity by transplanted organ, for example, a lower incidence of cancer in liver 
compared to heart and lung transplant recipients, as observed in this cohort (12). 
 
There are no prior published comparisons of immunosuppressive drug dosages by organ type. We 
comprehensively mapped the use of immunosuppressive agents over time since transplantation and by 
period, by organ type. Minimizing the degree of immunosuppression is the goal in long-term 
maintenance therapy, and this is achieved by reducing the number and/or the dosage of 
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immunosuppressive agents. We found that monotherapy was more commonly achieved in liver 
compared to heart and lung transplant recipients. We showed liver recipients received lower doses of 
azathioprine compared to heart and lung recipients at all follow-up times. There was no consistent 
pattern for CNIs, but liver recipients used a higher dose of cyclosporine compared to heart and lung 
transplant recipients at 5 years. On balance, liver recipients were shown to use a lower overall degree 
of immunosuppression than heart and lung transplant recipients.  
 
We found maintenance immunosuppression regimens used in liver transplantation were consistently 
different to those used in heart and lung transplantation. CNI monotherapy, first cyclosporine and 
increasingly tacrolimus, was used by around 40% of our liver cohort at any point in time. CNI-free 
regimens were rarely observed. Furthermore, prior to 1998 the uptake of tacrolimus in liver 
transplantation exceeded that in heart and lung transplantation, and after 1998 tacrolimus-based 
regimens were used by the majority of liver recipients. Corticosteroid withdrawal was also more 
common in liver transplantation. These patterns and trends are in alignment with data from the 
OPTN/SRTR in the US (1, 3), however, we did not see a decline in azathioprine in favor of 
mycophenolate. 
 
We showed a decline in the use of cyclosporine and azathioprine for heart transplantation since 1998, 
and an increase in tacrolimus- and mycophenolate-based regimens, consistent with international 
clinical practice trends (1, 13). In agreement with United States practice (1), we found changes in 
regimen during the latest period (1998-2006) occurred throughout follow-up but predominantly during 
the first year. 
 
Maintenance immunosuppressive therapy was very similar for lung and heart transplant recipients 
prior to 1998. Since 1998, use of tacrolimus-based therapies increased, more so in lung compared to 
heart recipients, in line with international trends (1, 14). During the latest period (1998-2006), the 
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most common regimen for lung transplant recipients at 1 year was cyclosporine-based, in contrast to 
international data during 2002-2011 showing majority use of tacrolimus-based regimens (14). 
However, by year 5, there was approximately equivalent use of cyclosporine- and tacrolimus-based 
regimens. In agreement with United States practice (1), during the latest period we observed the 
greatest variation in regimens over time since transplantation among lung transplant recipients, 
reflecting their higher incidence of late infections and chronic rejection, and the implementation of 
trial evidence on clinical efficacy. 
 
Our finding of higher adjusted rates of antibody induction in heart and lung compared to liver 
transplant recipients is consistent with unadjusted international and United States transplant registry 
data (1, 3, 15, 16). Overall, one third of recipients experienced at least one treated episode of acute 
rejection, more commonly in liver compared to heart and lung recipients. These observations are also 
comparable with international data for rejection during the first year after heart (30%; 2003-2008) (13), 
lung (34%; 2004-2011) (14), and liver transplantation in the United States (43%; 1998-2003) (17). In 
addition, we found a higher rate of rejection in pediatric heart recipients, as previously reported (13). 
In our data the timing of the acute rejection was not known, but the majority are expected to have 
occurred within one year of transplantation (3, 13, 18-20). As reported internationally (1, 3, 13), we 
observed a reduction in the incidence of acute rejection over time, a trend attributed to a wider range 
of immunosuppressive therapies, allowing tailoring of therapy to the individual. Whilst a number of 
factors related to transplantation including surgery, selection of donors and recipient management 
have changed over time, reductions in complications and mortality are predominantly attributed to 
improvements in immunosuppressive regimens and dosing over time. 
 
The key strengths of our study are the population-base and the adjusted comparison of 
immunosuppressive agents and dosages by organ type. The transplant registries included all 
recipients, thereby avoiding selection bias. As we had data on recipient and donor characteristics that 
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may influence the choice of immunosuppressive agents, we were able to compare organ groups taking 
into account potential confounding factors. On the other hand, several limitations must also be 
considered. Being a retrospective study, we were reliant on the availability and quality of medical 
records. We had missing data, to a greater extent for heart and lung compared to liver transplant 
recipients. As we used the last observation carried forward approach to missing data, we are likely to 
have underestimated changes in immunosuppressive regimen over time, and overestimated the dose 
with increasing time since transplantation. Reassuringly however, we observed no notable differences 
between the analysis carried out with the original and imputed data. We did not identify clinical trial 
participants or collect immunosuppression trough levels, thus the doses do not represent actual drug 
concentrations. In addition, we are unable to exclude residual confounding as an explanation for the 
differences by organ type because we did not have information on every characteristic that may 
influence the choice and dosage of immunosuppression after transplantation, such as infection, renal 
dysfunction, skin cancers, vasculopathy and bronchiolitis obliterans. 
 
Changes in immunosuppression regimens over time and across individuals indicate that observational 
research based on immunosuppression data at discharge after organ transplantation may misclassify 
recipients’ type of immunosuppressive therapy at later stages, potentially leading to spurious 
associations between immunosuppression and side-effects. Furthermore, given changes in the dose of 
immunosuppression with increasing time since transplantation, associations based on the discharge 
dose of immunosuppression may also be biased if the temporal changes differ for those on low 
compared to high discharge doses. The issue of potential misclassification and bias is an area of future 
study. 
  
We have used population-based data to address a question of long-standing interest in transplantation 
research. Our data reveals clear differences in immunosuppression therapies for Australian liver, heart 
and lung transplant recipients. We provide the first empirical evidence of a lower degree of immune 
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suppression in liver compared to heart and lung transplant recipients. We also demonstrate marked 
changes in immunosuppression over time since transplantation, both the dose and type of 
immunosuppression. These temporal changes should be taken into account in observational studies 
examining the relationship between iatrogenic immune suppression and post-transplantation outcomes. 
An important future extension of these findings will be an examination of post-transplantation 
outcomes in relation to longitudinal immunosuppression. 
 
  
 Page 16 of 21 
AUTHORS’ CONTRIBUTIONS 
Renhua Na, PhD: Conduct of study, data analysis, and drafting and approval of article; Maarit A. 
Laaksonen PhD: Conduct of study, data analysis, and critical revision and approval of article; Andrew 
E. Grulich PhD: Concept, secured funding, and critical revision and approval of article; Angela C. 
Webster PhD: Drafting, and critical revision and approval of article; Nicola S. Meagher MPH: 
Conduct of study and critical revision and approval of article; Geoffrey W. McCaughan PhD: Secured 
funding and approval of article; Anne M. Keogh PhD: Secured funding and critical revision and 
approval of article; Claire M. Vajdic PhD: Concept, secured funding, conduct of study, and drafting 
and approval of article. 
 
ACKNOWLEDGEMENTS 
This study was funded by the National Health and Medical Research Council (ID510254; ID568819 
to AEG; ID1053642 to ML; ID1023159 to CMV) and a Cancer Institute New South Wales Career 
Development Fellowship (ID10/CDF/2-42 to CMV). Renhua Na was supported by a Translational 
Cancer Research Network (TCRN) PhD Scholarship Top-up Award. The TCRN is a translational 
cancer research centre program funded by the Cancer Institute NSW. 
 
We thank the Australia and New Zealand Liver Transplant Registry, the Australian and New Zealand 
Cardiothoracic Organ Transplant Registry. We thank the following individuals for conducting and/or 
supporting the retrospective data collection: Phyllis Larkins (Royal Prince Alfred Hospital, Sydney); 
Geraldine Lipka (Princess Alexandra Hospital, Brisbane); Cassandra Kastaneas (St Vincent’s 
Hospital, Sydney); Vicki Jermyn and Brooke Andersen (The Children’s Hospital, Westmead); Jo 
Maddicks-Law, Nicole Ostenfeld, Sara Gray and Muhtashimuddin Ahmed (Prince Charles Hospital, 
Brisbane); Kerrie Beale (Royal Childrens Hospital, Brisbane); Libby John, Nicole Williams (Flinders 
Medical Centre, Adelaide); Kathryn Marshall, Ailsa Cowie, Connie Kambanaros, Jasmin Board, and 
Colleen Farrell (Alfred Hospital, Melbourne); Lyn Crellin, Kathe Beyerle, Kate Schurmann, Anne 
 Page 17 of 21 
Shipp, Janette McEwan, Danielle Kamolins, Angie Wood and Hollie Gilmore (Royal Childrens 
Hospital, Melbourne); Julie Pavlovic and Betheia Lele (Austin Hospital, Melbourne); Sharon 
Lawrence, Clare Wood and Sharlene Beinke (Royal Perth Hospital); Barb Chester, Judith Bull, Joanne 
Plummer, Nikki Copland and Megan O-Dea (Sir Charles Gairdner Hospital, Perth). 
 
The following lead investigators participated in this study: George Alex, Glenda Balderson, Peter 
Bergin, John Chen, Weng Chin, Lawrence Dembo, Pamela Dilworth, Looi Ee, Allan Glanville, Winita 
Hardikar, Peter Hopkins, George Javorsky, Gary P Jeffrey, Robert Jones, Bronwyn Levvey, Steven 
Lynch, Michael Musk, Ross Pettersson, Greg Snell, Michael Stormon, and Robert Weintraub. 
 
  
 Page 18 of 21 
FIGURE LEGENDS 
Figure 1. Study cohort exclusions and losses to follow-up 
Figure 2. Immunosuppressive drug combinations by time since transplantation for Australian liver, 
heart, and lung transplant recipients, 1984-1994  
Figure 3. Immunosuppressive drug combinations by time since transplantation for Australian liver, 
heart, and lung transplant recipients, 1995-1997 
Figure 4. Immunosuppressive drug combinations by time since transplantation for Australian liver, 
heart, and lung transplant recipients, 1998-2006 
Figure 5. Unadjusted and adjusted median dose of immunosuppressive agent by organ type 3 months 
after transplantation 
Figure 6. Unadjusted and adjusted median dose of immunosuppressive agent by organ type 1 year 
after transplantation 
Figure 7. Unadjusted and adjusted median dose of immunosuppressive agent by organ type 5 years 
after transplantation 
 
  
 Page 19 of 21 
SUPPLEMENTARY ONLINE INFORMATION 
Supplementary Table 1. Unadjusted and adjusted median doses (mg/kg/day) of individual 
immunosuppressive agents at 3 months, 1 year and 5 years after transplantation in Australian heart, 
lung and liver transplant recipients 
Supplementary Figure 1. Immunosuppressive drug combinations 3 months after transplantation in 
Australian liver, heart, and lung transplant recipients, by era 
Supplementary Figure 2. Immunosuppressive drug combinations 1 year after transplantation in 
Australian liver, heart, and lung transplant recipients, by era 
Supplementary Figure 3. Immunosuppressive drug combinations 5 years after transplantation in 
Australian liver, heart, and lung transplant recipients, by era 
Supplementary Figure 4. Immunosuppressive drug combinations at 10 years after transplantation in 
Australian liver, heart, and lung transplant recipients, by era 
Supplementary Figure 5. Change in median cyclosporine and tacrolimus dose (q1-q3, mg/kg/day) by 
time since transplantation and type of organ  
Supplementary Figure 6. Change in median mycophenolate and azathioprine dose (q1-q3, 
mg/kg/day) by time since transplantation and type of organ 
 
  
 Page 20 of 21 
REFERENCES 
1. Meier-Kriesche HU, Li S, Gruessner RWG, Fung JJ, Bustami RT, Barr ML, et al. 
Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant 2006; 6: 
1111. 
2. Singh S, Watt KD. Long-term medical management of the liver transplant recipient: What the 
primary care physician needs to know. Mayo Clin Proc 2012; 87: 779. 
3. Wiesner RH, Fung JJ. Present state of immunosuppressive therapy in liver transplant 
recipients. Liver Transpl 2011; 17: S1. 
4. Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of 
malignancy in recipients of different types of organ: a UK registry audit. Am J Transplant 
2010; 10: 1889. 
5. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The international 
society of heart and lung transplantation guidelines for the care of heart transplant recipients. J 
Heart Lung Transplant 2010; 29: 914. 
6. Allison P. Missing data. Thousand Oaks, CA: Sage: Sage University Papers Series on 
Quantitative Applications in the Social Sciences; 2001. 
7. Rubin D. Inference and missing data. Biometrika 1976; 63: 581  
8. Staatz C, Tett S. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid 
organ transplant recipients. Clin Pharmacokinet 2007; 46: 13. 
9. Committee for Medicinal Products for Human use. Guideline on missing data in confirmatory 
clinical trials. London: European Medicines Agency; 2010. 
10. Elliott AC, Hynan LS. A SAS® macro implementation of a multiple comparison post hoc test 
for a Kruskal–Wallis analysis. Comput Methods Programs Biomed. 2011; 102: 75. 
11. McGreevy KM, Lipsitz SR, Linder JA, Rimm E, Hoel DG. Using median regression to obtain 
adjusted estimates of central tendency for skewed laboratory and epidemiologic data. Clin 
Chem 2009; 55: 165. 
 Page 21 of 21 
12. Na R, Grulich AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. Comparison of de 
novo cancer incidence in Australian liver, heart and lung transplant recipients. Am J 
Transplant 2013; 13: 174. 
13. Stehlik J, Edwards LB, Kucheryavaya AY, Aurora P, Christie JD, Kirk R, et al. The Registry 
of the International Society for Heart and Lung Transplantation: twenty-seventh official adult 
heart transplant report--2010. J Heart Lung Transplant 2010; 29: 1089. 
14. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, et al. The 
registry of the international society for heart and lung transplantation: 29th adult lung and 
heart-lung transplant report—2012. J Heart  Lung Transplant 2012; 31: 1073. 
15. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Waltz DA, Keck BM, et al. Registry of 
the international society for heart and lung transplantation: twenty-third official adult heart 
transplantation report--2006. J Heart Lung Transplant 2006; 25: 869. 
16. Trulock EP, Edwards LB, Taylor DO, Boucek MM, Keck BM, Hertz MI. Registry of the 
international society for heart and lung transplantation: Twenty-third official adult lung and 
heart–lung transplantation report—2006. J Heart Lung Transplant 2006; 25: 880. 
17. Shaked A, Ghobrial RM, Merion RM, Shearon TH, Emond JC, Fair JH, et al. Incidence and 
severity of acute cellular rejection in recipients undergoing adult living donor or deceased 
donor liver transplantation. Am J Transplant 2009; 9: 301. 
18. Yusen RD, Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, et al. The 
registry of the international society for heart and lung transplantation: Thirtieth adult lung and 
heart-lung transplant report—2013; focus theme: Age. J Heart Lung Transplant 2013; 32: 965. 
19. Martinu T, Pavlisko EN, Chen DF, Palmer SM. Acute allograft rejection: cellular and humoral 
processes. Clin Chest Med 2011; 32: 295. 
20. Martinu T, Chen DF, Palmer SM. Acute rejection and humoral sensitization in lung transplant 
recipients. Proc Am Thorac Soc 2009; 6: 54. 
 
